CA+2 AND NA+ TRANSPORT AND ARRHYTHMIAS IN HEART FAILURE

心力衰竭中的 CA 2 和 NA 转运和心律失常

基本信息

  • 批准号:
    6087994
  • 负责人:
  • 金额:
    $ 47.01万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2000
  • 资助国家:
    美国
  • 起止时间:
    2000-07-05 至 2004-06-30
  • 项目状态:
    已结题

项目摘要

The goal of these studies is to define the role of altered Ca and Na transport in the development of ventricular tachycardia (VT) in heart failure (HF). We have recently shown that VT in the failing rabbit & human heart initiates by a nonreentrant" mechanism that may be due to triggered activity from delayed afterdepolarizations (DADs) (or early afterdepolarizations, EADs). We also find upregulation of Na/Ca exchange (NaCaX) mRNA, protein and current in HF which could underlie the transient inward current (I-ti) responsible for DADs. We hypothesize that in HF, prolongation of the action potential duration (APD) and increased [Na]1 (due to decreased Na/K ATPase activity) contribute to SR Ca overload and spontaneous SR Ca release. Further, a given SR Ca release in HF will produce greater I-ti (due to increased NaCaX) and larger DADs (due to increased I-ti and reduced 1-K1), resulting in more triggered APs and nonreentrant arrhythmias in HF. Specific Aims will focus on: l. The role of altered APD & ionic currents on both SR Ca load and DAD induction in HF. 2. The alterations in intracellular [Na] and Na/K-ATPase activity & expression in HF. 3. The relationship of SR Ca release to the genesis of arrhythmogenic I- ti's, DADs and triggered APs. 4. The possible contribution of spontaneous SR Ca release to EADs in HF. 5. The effects of blocking Ca influx via NaCaX (with KB-R7943) on E-C coupling, on prevention of I-ti and DADs in myocytes, and on prevention of VT in the intact failing heart in situ. The experimental approaches will include: in vitro patch clamping (voltage, AP & current clamp); fluorescence measurements of [Ca]i and [Na]i; measurement of mRNA & protein (of Ca transporters & Na/K ATPase subunit isoforms) and Na/K ATPase activity; and 3-dimensional cardiac mapping in vivo. Detailed studies in a novel arrhythmogenic rabbit model of nonischemic HF will be extended to include studies in isolated ventricular myocytes from failing and nonfailing human hearts. The results of these studies will provide the foundation for the development of effective therapeutic approaches to modulate nonreentrant initiation of VT and to decrease the high incidence of sudden death in patients with heart failure.
这些研究的目的是确定钙和钠转运改变在心力衰竭(HF)室性心动过速(VT)发展中的作用。我们最近的研究表明,在衰竭的家兔和人类心脏中,室性心动过速是由一种非折返性机制引发的,这种机制可能是由于延迟后除极(DAD)(或早期后除极,埃兹)触发的。我们还发现HF中Na/Ca交换(NaCaX)mRNA、蛋白和电流的上调,这可能是导致DAD的瞬时内向电流(I-ti)的基础。我们假设在HF中,动作电位时程(APD)的延长和[Na]1增加(由于Na/K ATP酶活性降低)有助于SR Ca超载和自发SR Ca释放。此外,HF中给定的SR Ca释放将产生更大的I-ti(由于NaCaX增加)和更大的DAD(由于I-ti增加和1-K1减少),导致HF中更多的触发AP和非折返性心律失常。具体目标将集中在:l。改变APD和离子电流对HF中SR Ca负荷和DAD诱导的作用。2. HF中细胞内[Na]和Na/K-ATP酶活性及表达的改变。3. SR Ca释放与致炎性I- ti's、DAD和触发性AP发生的关系。4.自发性SR Ca释放对HF中埃兹的可能贡献。5.通过NaCaX(用KB-R7943)阻断Ca内流对E-C偶联、对预防心肌细胞中的I-ti和DAD以及对预防原位完整衰竭心脏中的VT的影响。实验方法将包括:体外膜片钳(电压、AP和电流钳);[Ca]i和[Na]i的荧光测量; mRNA和蛋白质(Ca转运蛋白和Na/K ATP酶亚基亚型)和Na/K ATP酶活性的测量;以及体内三维心脏标测。在一种新的致瘤兔非缺血性HF模型中的详细研究将扩展到包括在来自衰竭和非衰竭人类心脏的分离心室肌细胞中的研究。这些研究的结果将为开发有效的治疗方法提供基础,以调节非折返性VT的起始,并降低心力衰竭患者猝死的高发生率。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Donald M Bers其他文献

The Difference of Calmodulin-Ryanodine Receptor Affinity Between N-terminal, Central and C-terminal RyR2-CPVT Knock-in Mice
N端、中央端和C端RyR2-CPVT敲入小鼠钙调蛋白-兰尼定受体亲和力的差异
  • DOI:
  • 发表时间:
    2019
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Hitoshi Uchinoumi;Xiaoqiong Dong;Ivanita Stefanon;Mena Said;Rogerio Faustino;Razvan L Cornea;Univ of Minnesota;Xander H.t. Wehrens; Takeshi Yamamoto;Masafumi Yano;Donald M Bers
  • 通讯作者:
    Donald M Bers
Beyond beta blockers
超越β受体阻滞剂
  • DOI:
    10.1038/nm0405-379
  • 发表时间:
    2005-04-01
  • 期刊:
  • 影响因子:
    50.000
  • 作者:
    Donald M Bers
  • 通讯作者:
    Donald M Bers

Donald M Bers的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Donald M Bers', 18)}}的其他基金

Training Program in Pharmacology
药理学培训计划
  • 批准号:
    10656570
  • 财政年份:
    2022
  • 资助金额:
    $ 47.01万
  • 项目类别:
Systems Approach to Understanding Cardiovascular Disease and Arrhythmias - Cell diversity in the cardiovascular system, cell-autonomous and cell-cell signaling
了解心血管疾病和心律失常的系统方法 - 心血管系统中的细胞多样性、细胞自主和细胞间信号传导
  • 批准号:
    10386681
  • 财政年份:
    2021
  • 资助金额:
    $ 47.01万
  • 项目类别:
Systems Approach to Understanding Cardiac Arrhythmias Mechanisms
了解心律失常机制的系统方法
  • 批准号:
    9763307
  • 财政年份:
    2019
  • 资助金额:
    $ 47.01万
  • 项目类别:
Project 2 (Bers)
项目2(Bers)
  • 批准号:
    10677715
  • 财政年份:
    2019
  • 资助金额:
    $ 47.01万
  • 项目类别:
Project 2 (Bers)
项目2(Bers)
  • 批准号:
    10006341
  • 财政年份:
    2019
  • 资助金额:
    $ 47.01万
  • 项目类别:
Modelling structural and functional heterogeneity in heart failure reveals arrhythmic impact
心力衰竭的结构和功能异质性建模揭示了心律失常的影响
  • 批准号:
    10199780
  • 财政年份:
    2019
  • 资助金额:
    $ 47.01万
  • 项目类别:
Modelling structural and functional heterogeneity in heart failure reveals arrhythmic impact
心力衰竭的结构和功能异质性建模揭示了心律失常的影响
  • 批准号:
    10449125
  • 财政年份:
    2019
  • 资助金额:
    $ 47.01万
  • 项目类别:
Project 2 (Bers)
项目2(Bers)
  • 批准号:
    10249148
  • 财政年份:
    2019
  • 资助金额:
    $ 47.01万
  • 项目类别:
Project 2 (Bers)
项目2(Bers)
  • 批准号:
    10471339
  • 财政年份:
    2019
  • 资助金额:
    $ 47.01万
  • 项目类别:
CaMKII activation and regulation in adult cardiac myocytes
成人心肌细胞中 CaMKII 的激活和调节
  • 批准号:
    10687251
  • 财政年份:
    2018
  • 资助金额:
    $ 47.01万
  • 项目类别:

相似海外基金

DEVELOPING A HUMAN STEM CELL-DERIVED HEART MODEL TO CHARACTERIZE A NOVEL ARRHYTHMIA SYNDROME
开发人类干细胞衍生的心脏模型来表征新型心律失常综合征
  • 批准号:
    495592
  • 财政年份:
    2023
  • 资助金额:
    $ 47.01万
  • 项目类别:
Preliminary Study to Establish Heavy Ion Ablation Therapy for Lethal Ventricular Arrhythmia
重离子消融治疗致死性室性心律失常的初步研究
  • 批准号:
    23K14885
  • 财政年份:
    2023
  • 资助金额:
    $ 47.01万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Arrhythmia Mechanisms Modulated by Intercalated Disc Extracellular Nanodomains
闰盘细胞外纳米结构域调节心律失常的机制
  • 批准号:
    10668025
  • 财政年份:
    2023
  • 资助金额:
    $ 47.01万
  • 项目类别:
Development of a next-generation telemonitoring system for prognostic prediction of the onset of heart failure and arrhythmia
开发下一代远程监测系统,用于心力衰竭和心律失常发作的预后预测
  • 批准号:
    23K09597
  • 财政年份:
    2023
  • 资助金额:
    $ 47.01万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The role of inflammation in the pathogenesis of atrial fibrillation: Implications for atrial remodeling pathophysiology and for early atrial arrhythmia recurrences following radiofrequency ablation and pulsed field ablation
炎症在心房颤动发病机制中的作用:对心房重塑病理生理学以及射频消融和脉冲场消融后早期房性心律失常复发的影响
  • 批准号:
    514892030
  • 财政年份:
    2023
  • 资助金额:
    $ 47.01万
  • 项目类别:
    WBP Fellowship
Improved arrhythmia ablation via MR-guided robotic catheterization and multimodal clinician feedback
通过 MR 引导的机器人导管插入术和多模式临床医生反馈改善心律失常消融
  • 批准号:
    10638497
  • 财政年份:
    2023
  • 资助金额:
    $ 47.01万
  • 项目类别:
Prototype development and validation of soft robotic sensor arrays for mapping cardiac arrhythmia
用于绘制心律失常的软机器人传感器阵列的原型开发和验证
  • 批准号:
    10722857
  • 财政年份:
    2023
  • 资助金额:
    $ 47.01万
  • 项目类别:
A novel regulator of Ca2+ homeostasis and arrhythmia susceptibility
Ca2 稳态和心律失常易感性的新型调节剂
  • 批准号:
    10724935
  • 财政年份:
    2023
  • 资助金额:
    $ 47.01万
  • 项目类别:
Novel Stellate Ganglia Chemo-ablation Approach to Treat Cardiac Arrhythmia and Cardiac Remodeling in Heart Failure
新型星状神经节化疗消融方法治疗心律失常和心力衰竭心脏重塑
  • 批准号:
    10727929
  • 财政年份:
    2023
  • 资助金额:
    $ 47.01万
  • 项目类别:
The role N-terminal acetylation in dilated cardiomyopathy and associated arrhythmia
N-末端乙酰化在扩张型心肌病和相关心律失常中的作用
  • 批准号:
    10733915
  • 财政年份:
    2023
  • 资助金额:
    $ 47.01万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了